Drug Trial Radar · NCT06447662
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
64
Actual
Start
Jun 27, 2024
Primary completion
Oct 9, 2026
Study completion Oct 9, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.
Conditions
- Carcinoma, Pancreatic Ductal
- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
Interventions
PF-07934040Drug
panKRAS inhibitor
GemcitabineCombination product
Chemotherapy (antimetabolite)
Nab-paclitaxelCombination product
Taxane-type Chemotherapy
CetuximabCombination product
Monoclonal Antibody (EGFR Inhibitor)
FluorouracilCombination product
Part of FOLFOX chemotherapy regimen cytotoxic chemotherapy (antimetabolite and pyrimidine analog)
OxaliplatinCombination product
Part of FOLFOX Chemotherapy Regimen platinum based compound (alkylating agent)
LeucovorinCombination product
Part of FOLFOX chemotherapy regimen Folic Acid Analog
BevacizumabCombination product
VEG-F inhibitor
PembrolizumabCombination product
immune checkpoint inhibitor (PD-1 inhibitor)
pemetrexedCombination product
Can be used in Platinum-based Chemotherapy regimen Antimetabolite
CisplatinCombination product
Can be used as part of Platinum-based chemotherapy regimen Platinum-based antineoplastic (alkylating agent)
PaclitaxelCombination product
Can be used in Platinum-based chemotherapy regimen Taxane
CarboplatinCombination product
Can be used as part of a platinum-based chemotherapy regimen platinum containing compound (alkylating agent)
SasanlimabCombination product
immune checkpoint inhibitor (PD-1 inhibitor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 & 2: Incidence of Adverse Events (AEs)Time frame: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
- PART 1 & 2: Number of participants with laboratory abnormalitiesTime frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
- Part 1: Number of participants with Dose-limiting toxicities (DLT)Time frame: Baseline up to 28 days
- Part 2: Objective Response - Number of Participants With Objective Response (alone or in combination)Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Highlands Oncology Group, PA
Fayetteville, Arkansas
Highlands Oncology Group, PA
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
City of Hope Investigational Drug Service (IDS)
Duarte, California
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)
Aurora, Colorado
University of Colorado Hospital - Anschutz Outpatient Pavilion
Aurora, Colorado
University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)
Aurora, Colorado
University of Colorado Hospital
Aurora, Colorado
Sibley Memorial Hospital
Washington D.C., District of Columbia
START Midwest
Grand Rapids, Michigan
Siteman Cancer Center - St Peters
City of Saint Peters, Missouri
Siteman Cancer Center - West County
Creve Coeur, Missouri
Siteman Cancer Center - North County
Florissant, Missouri
Siteman Cancer Center
St Louis, Missouri
Barnes-Jewish Hospital
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center - South County
St Louis, Missouri
Duke University Medical Center, lnvestigational Chemotherapy Service
Durham, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
West Chester Hospital
West Chester, Ohio
Rhode Island Hospital
Providence, Rhode Island
Miriam Hospital
Providence, Rhode Island
University of Texas MD Anderson Cancer Center
Houston, Texas
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.